Cardiometabolic Risk Factors in Rosuvastatin-Treated Men with Mixed Dyslipidemia and Early-Onset Androgenic Alopecia

    May 2021 in “ Molecules ”
    Robert Krysiak, Marcin Basiak, Bogusław Okopień
    Studysummary This study found that men with early-onset androgenetic alopecia may experience less benefit from rosuvastatin treatment in terms of improving cardiometabolic risk factors compared to men with normal hair growth.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on mdpi.com →
    Discuss this study in the Community →

    Research cited in this study 7

    1. Polycystic Ovary Syndrome: Comprehensive Overview Obstetrics & Gynecology · 2018
    2. Gynecologic and Andrologic Dermatology and the Metabolic Syndrome Clinics in Dermatology · 2017
    3. Alopecia and the Metabolic Syndrome Clinics in Dermatology · 2017
    4. Polycystic Ovary Syndrome in Men Medical Hypotheses · 2017
    5. Androgenetic Alopecia: A Review Endocrine · 2017
    6. Androgenetic Alopecia: An Update Of Treatment Options Drugs · 2016
    7. A Comparison of the Hormonal Profile of Early Androgenetic Alopecia in Men With the Phenotypic Equivalent of Polycystic Ovarian Syndrome in Women JAMA Dermatology · 2016